NetraMark Holdings Inc., a Toronto-based company specializing in AI technology for the pharmaceutical industry, celebrated its new listing on the Toronto Stock Exchange (TSX). Their flagship AI product, NetraAI, analyzes complex clinical trial data to identify patient subgroups and treatment signals that traditional methods miss, helping to optimize trial design and decision-making. This listing marks a significant step for NetraMark as it aims to support better clinical development and precision medicine. The company’s leadership, alongside TSX officials, officially opened the market to mark the occasion.
Charles Schwab announced record second-quarter results with $7.07 billion in revenue and $1.62 adjusted EPS, a 42% increase year-over-year. The company added 1.4 million new brokerage accounts and $120 billion in net new assets, signaling strong clie...
D.R. Horton reported strong quarterly earnings with an EPS of $3.20 and revenue of $9.23 billion, both exceeding analyst expectations. The results were driven by a 4% increase in home-closing volumes, totaling nearly 24,000 homes, along with contribu...
The U.S. Small Business Administration (SBA) announced a $6 million grant competition to fund the Women’s Business Center (WBC) Modernization Initiative. This initiative aims to expand statewide support networks for women entrepreneurs in eight state...
Copart's stock is under pressure following a Barclays analyst downgrade to a $26 price target and significant insider selling by a company director. The company faces a securities fraud investigation after CEO Jeff Liaw's resignation, which caused an...
Charles Schwab reported strong Q2 2026 results with earnings per share of $1.62, exceeding estimates and marking a 42% increase year-over-year. The company achieved record quarterly revenue of $7.07 billion, driven by increased trading activity and h...
